Inhibrx Biosciences cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 12 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Net Income | -47.05M | -51.79M | -91.97M | -78.71M | 1,858.01M | -43.86M | -47.87M | -43.31M | -28.65M | -35.26M | -32.83M | -36.65M |
| Share-based Compensation | 6.53M | 6.43M | 6.40M | 46.17M | 2.98M | 2.45M | 2.77M | 2.74M | ||||
| Cash from Operations | -54.24M | -56.82M | -63.05M | -57.36M | -30.28M | -43.72M | -35.90M | -29.95M | -33.82M | -30.12M | ||
| Depreciation, Depletion & Amortization | ||||||||||||
| Amortization of Deferred Charges | 1.24M | 1.25M | 1.24M | 0.82M | 0.53M | 0.63M | 0.64M | 0.64M | ||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.29M | 0.30M | 0.30M | 0.36M | 0.47M | 0.76M | 0.69M | 0.68M | 0.66M | 0.58M | 0.56M | 0.52M |
| Change in Working Capital | ||||||||||||
| Change in Receivables | 0.00M | 0.45M | 0.10M | 0.09M | -0.18M | 0.06M | -0.13M | 0.05M | ||||
| Change in Account Payables | -1.59M | 2.91M | 4.05M | 17.42M | -0.45M | -3.12M | -0.35M | -0.60M | -1.52M | -0.83M | ||
| Change in Accured Expenses | 6.35M | 17.39M | 8.03M | 21.82M | 6.03M | 2.88M | -4.30M | -1.51M | -1.43M | |||
| Other Working Capital Changes | 15.14M | -8.98M | 2.36M | 1.08M | -4.78M | -1.64M | -0.73M | -0.22M | -0.11M | -0.54M | ||
| Investing Activities | ||||||||||||
| Capital Expenditures | 0.57M | 3.44M | 1.42M | 2.16M | -0.03M | 0.12M | -0.03M | 0.01M | 0.05M | |||
| Cash from Investing Activities | -0.81M | -3.44M | -1.12M | -1.22M | -0.25M | -0.02M | -0.02M | -0.01M | ||||
| Financing Activities | ||||||||||||
| Other financing activities | 198.79M | 38.73M | 32.95M | 0.35M | 1.25M | |||||||
| Debt Issuance and Repayment | ||||||||||||
| Long-Term Debt Issuances | 99.97M | |||||||||||
| Misc. | ||||||||||||
| Cash from Financing Activities | 199.89M | 0.86M | 38.73M | 32.95M | 99.84M | 0.35M | 1.25M | |||||
| Change in Cash | 144.84M | -59.40M | -25.44M | -25.62M | -30.53M | -43.74M | 63.92M | -29.95M | -33.48M | -28.87M | ||
| Free Cash Flow | -54.81M | -60.26M | -64.47M | -59.52M | -30.25M | -43.84M | -35.87M | -29.96M | -33.88M | -30.12M | ||
| Net Cash Flow | 144.84M | -59.40M | -25.44M | -25.62M | -30.53M | -43.74M | 63.92M | -29.95M | -33.48M | -28.87M |